Evofem Biosciences, Inc. (EVFM)
OTCMKTS · Delayed Price · Currency is USD
0.0060
-0.0007 (-10.45%)
At close: May 5, 2026
Evofem Biosciences Revenue
In the year 2025, Evofem Biosciences had annual revenue of $20.18M with 4.23% growth. Evofem Biosciences had revenue of $9.56M in the quarter ending December 31, 2025, with 34.59% growth.
Revenue
20.18M
Revenue Growth
+4.23%
P/S Ratio
0.04
Revenue / Employee
695.97K
Employees
29
Market Cap
795.18K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.18M | 820.00K | 4.23% |
| Dec 31, 2024 | 19.36M | 1.15M | 6.28% |
| Dec 31, 2023 | 18.22M | 1.38M | 8.20% |
| Dec 31, 2022 | 16.84M | 8.59M | 104.23% |
| Dec 31, 2021 | 8.24M | 7.80M | 1,748.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Adaptimmune Therapeutics | 65.09M |
| Emmaus Life Sciences | 12.45M |
| SQZ Biotechnologies Company | 12.12M |
| Eastgate Biotech | 137.64K |
| Halberd | 6.94K |
| Aibotics | 2.18K |
Evofem Biosciences News
- 8 days ago - Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa - Business Wire
- 7 weeks ago - Evofem Reports Fifth Consecutive Year of Net Sales Growth - Business Wire
- 3 months ago - Evofem CEO Saundra Pelletier Calls for a “Ground-Up Reset” of Women's Health at Fierce JPM Week 2026 - Business Wire
- 3 months ago - Evofem Expands “Say Vagina” Campaign With Launch of Say Vagina Store - Business Wire
- 5 months ago - Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE - PRNewsWire
- 6 months ago - Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update - PRNewsWire
- 7 months ago - Evofem Announces Voting Results from Special Meeting of Stockholders - PRNewsWire
- 7 months ago - Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates - PRNewsWire